Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pasithea Therapeutics (KTTA) Gains from Sales and Divestitures (2021 - 2023)

Pasithea Therapeutics (KTTA) has disclosed Gains from Sales and Divestitures for 2 consecutive years, with $5832.0 as the latest value for Q4 2023.

  • Quarterly Gains from Sales and Divestitures changed N/A to $5832.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $5832.0 through Dec 2023, changed N/A year-over-year, with the annual reading at $5832.0 for FY2023, N/A changed from the prior year.
  • Gains from Sales and Divestitures hit $5832.0 in Q4 2023 for Pasithea Therapeutics, down from $100000.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $100000.0 in Q4 2021 to a low of $5832.0 in Q4 2023.